Anixa Biosciences Past Earnings Performance
Past criteria checks 0/6
Anixa Biosciences's earnings have been declining at an average annual rate of -1.2%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 19.2% per year.
Key information
-1.2%
Earnings growth rate
10.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -19.2% |
| Return on equity | -60.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
No updates
Recent updates
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?
Dec 19
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Revenue & Expenses Breakdown
How Anixa Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 0 | -12 | 7 | 7 |
| 30 Apr 24 | 0 | -12 | 7 | 6 |
| 31 Jan 24 | 0 | -11 | 7 | 5 |
| 31 Oct 23 | 0 | -10 | 6 | 5 |
| 31 Jul 23 | 0 | -11 | 7 | 5 |
| 30 Apr 23 | 0 | -11 | 6 | 5 |
| 31 Jan 23 | 0 | -12 | 7 | 6 |
| 31 Oct 22 | 0 | -14 | 7 | 7 |
| 31 Jul 22 | 0 | -14 | 7 | 7 |
| 30 Apr 22 | 0 | -16 | 8 | 8 |
| 31 Jan 22 | 0 | -15 | 8 | 7 |
| 31 Oct 21 | 1 | -13 | 7 | 6 |
| 31 Jul 21 | 1 | -11 | 7 | 4 |
| 30 Apr 21 | 1 | -9 | 6 | 4 |
| 31 Jan 21 | 1 | -10 | 6 | 4 |
| 31 Oct 20 | 0 | -10 | 6 | 4 |
| 31 Jul 20 | 0 | -10 | 5 | 5 |
| 30 Apr 20 | 0 | -9 | 5 | 5 |
| 31 Jan 20 | 0 | -9 | 5 | 5 |
| 31 Oct 19 | 0 | -12 | 6 | 5 |
| 31 Jul 19 | 0 | -15 | 7 | 7 |
| 30 Apr 19 | 1 | -18 | 8 | 9 |
| 31 Jan 19 | 1 | -17 | 8 | 8 |
| 31 Oct 18 | 1 | -14 | 7 | 7 |
| 31 Jul 18 | 1 | -10 | 6 | 5 |
| 30 Apr 18 | 1 | -7 | 5 | 2 |
| 31 Jan 18 | 0 | -5 | 5 | 2 |
| 31 Oct 17 | 0 | -7 | 4 | 2 |
| 31 Jul 17 | 1 | -6 | 4 | 2 |
| 30 Apr 17 | 0 | -6 | 3 | 2 |
| 31 Jan 17 | 0 | -7 | 3 | 2 |
| 31 Oct 16 | 0 | -5 | 3 | 2 |
| 31 Jul 16 | 0 | -5 | 3 | 2 |
| 30 Apr 16 | 0 | -6 | 3 | 2 |
| 31 Jan 16 | 0 | -7 | 5 | 1 |
| 31 Oct 15 | 0 | -1 | 6 | 1 |
| 31 Jul 15 | 2 | -3 | 7 | 0 |
| 30 Apr 15 | 3 | -1 | 6 | 0 |
| 31 Jan 15 | 4 | -2 | 6 | 0 |
| 31 Oct 14 | 4 | -10 | 6 | 0 |
| 31 Jul 14 | 3 | -9 | 7 | 0 |
| 30 Apr 14 | 1 | -12 | 8 | 0 |
| 31 Jan 14 | 0 | -12 | 8 | 0 |
Quality Earnings: ANIX is currently unprofitable.
Growing Profit Margin: ANIX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANIX is unprofitable, and losses have increased over the past 5 years at a rate of 1.2% per year.
Accelerating Growth: Unable to compare ANIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ANIX has a negative Return on Equity (-60.44%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 09:15 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2023/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anixa Biosciences, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jason Kolbert | D. Boral Capital LLC. |
| Yi Chen | H.C. Wainwright & Co. |